Pulike Biological Engineering Inc
SSE:603566
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Pulike Biological Engineering Inc
Short-Term Debt
Pulike Biological Engineering Inc
Short-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Short-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
Pulike Biological Engineering Inc
SSE:603566
|
Short-Term Debt
¥0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Short-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Short-Term Debt
¥68.9m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
20%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Short-Term Debt
¥311.5m
|
CAGR 3-Years
-57%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
-9%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Short-Term Debt
¥675.2m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-8%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Short-Term Debt
¥603.8m
|
CAGR 3-Years
49%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
Pulike Biological Engineering Inc
Glance View
Pulike Biological Engineering, Inc. engages in the research, development, manufacturing and sale of biological products for animals, chemical drugs and Chinese veterinary drugs. The company is headquartered in Luoyang, Henan and currently employs 1,809 full-time employees. The company went IPO on 2015-05-18. Inc is principally engaged in the research, development, production and distribution of veterinary biological products and chemical medicines. The firm's veterinary biological products include vaccine and antibody, applied in the prevention and controlling of infection to epidemic disease for poultry and livestock. Its veterinary chemical medicines are mainly used in the treatment of epidemic diseases of poultry and livestock.
See Also
What is Pulike Biological Engineering Inc's Short-Term Debt?
Short-Term Debt
0
CNY
Based on the financial report for Sep 30, 2025, Pulike Biological Engineering Inc's Short-Term Debt amounts to 0 CNY.
